Faropenem medoxomil

Drug Profile

Faropenem medoxomil

Alternative Names: A0026; BAY 56-6854; Faropenem daloxate; SUN 208; SUN A0026

Latest Information Update: 04 Aug 2011

Price : $50

At a glance

  • Originator Asubio Pharma
  • Developer Cardiovascular Systems; Replidyne
  • Class Antibacterials; Beta-lactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia
  • No development reported Anthrax; Otitis media; Pharyngitis; Tonsillitis
  • Discontinued Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 26 Feb 2009 Replidyne is now called Cardiovascular Systems, Inc.
  • 28 Oct 2008 Efficacy and safety data from a phase III trial in Acute exacerbations of chronic bronchitis presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008)
  • 24 Apr 2008 Suspended - Phase-III for Community-acquired pneumonia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top